A Phase 4 interventional study of Hydrocortisone in Hyperglycemia, sponsored by Srinakharinwirot University. Completed at 1 site in Thailand. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-10-06.
Sponsored by Srinakharinwirot University · Phase 4, Interventional, and Treatment
The purpose of this study is to compare hyperglycemia and other effects, include 28-day mortality and time to reversal of shock between 100 milligrams and 200 milligrams of hydrocortisone as initial dosage in patients with septic shock.
The intervention group will be received 100 milligrams per day of hydrocortisone on the first three day the taper off, whereas the control group will be received 200 milligrams per day of hydrocortisone on the first three day the taper off. Hyperglycemia rate will be monitored every 6 hours after hydrocortisone is started until 24 hours after it is stopped.
Also, 28-day mortality will be follow after hydrocortisone is started.
699 studies on the registry are indexed under Hyperglycemia; 105 are open to participants now.
This study's enrollment of 80 is above the median of 46 across 521 interventional studies indexed under Hyperglycemia.
Browse Hyperglycemia studies →Srinakharinwirot University is the lead sponsor of 11 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
100 milligrams per day of hydrocortisone is the starting dosage.
Drug: Hydrocortisone
200 milligrams per day of hydrocortisone is the starting dosage.
Drug: Hydrocortisone
Subjects will be divided into two groups by randomization. The intervention-group will be received 100 milligrams per day of hydrocortisone and the control-group will be received 200 milligrams per day of hydrocortisone in the first three days after enrollment.
Also known as: solu cortef
Hyperglycemia
Proportion of hyperglycemic patients
Time frame: two years
28-day mortality
The number of the patients who died before or at 28 days after enrollment.
Time frame: two years
Time to shock reversal
The dates when vasopressors can be stopped.
Time frame: two years
This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Srinakharinwirot University